Kiniksa Pharmaceuticals International (NASDAQ: KNSA) revenue
Kiniksa Pharmaceuticals International reported revenue of $677.6m for fiscal 2025, 60.1% more than in fiscal 2024 ($423.2m). Since fiscal 2021 its revenue has grown by 1,657.9%, an average growth of 104.8% a year.
Kiniksa Pharmaceuticals International has grown its revenue for 4 years in a row, and fiscal 2025 is the highest of its 5 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $677.6m | +60.1% | $77.2m | 11.4% |
| 2024 | $423.2m | +56.6% | −$45.6m | −10.8% |
| 2023 | $270.3m | +22.7% | −$25.2m | −9.3% |
| 2022 | $220.2m | +471.2% | $9.8m | 4.4% |
| 2021 | $38.5m | — | −$156.6m | −406.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Kiniksa Pharmaceuticals International revenue compared with its sector
By revenue for its latest fiscal year, Kiniksa Pharmaceuticals International ranks 177th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Kiniksa Pharmaceuticals International, 60.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 175th | Pacira Biosciences | $726.4m | 3.6% |
| 176th | Amphastar Pharmaceuticals | $719.9m | −1.7% |
| 177th | Kiniksa Pharmaceuticals International | $677.6m | 60.1% |
| 178th | Ultragenyx Pharmaceutical | $673.0m | 20.2% |
| 179th | Doximity | $644.9m | 13.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Kiniksa Pharmaceuticals International
- How much revenue did Kiniksa Pharmaceuticals International make in fiscal 2025?
- Kiniksa Pharmaceuticals International reported revenue of $677.6m for fiscal 2025, compared with $423.2m in fiscal 2024.
- How much has the revenue of Kiniksa Pharmaceuticals International grown?
- Between fiscal 2021 and fiscal 2025 it went from $38.5m to $677.6m: 1,657.9% more, an average growth of 104.8% a year.
- What was the best year for revenue at Kiniksa Pharmaceuticals International?
- Of its last 5 fiscal years, fiscal 2025, with $677.6m.
- Where does Kiniksa Pharmaceuticals International rank in its sector by revenue?
- It ranks 177th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Kiniksa Pharmaceuticals International come from?
- From the annual report (Form 10-K) that Kiniksa Pharmaceuticals International files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Kiniksa Pharmaceuticals International files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Kiniksa Pharmaceuticals International: the Kiniksa Pharmaceuticals International page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.